Effect of Prostaglandin E1 on arteriosclerosis obliterans in diabetic patients

被引:0
|
作者
Sano, H [1 ]
Narimiya, M [1 ]
Matsushima, M [1 ]
Asao, K [1 ]
Takemura, T [1 ]
Kawaguchi, M [1 ]
Tajima, N [1 ]
Hiratsuka, A [1 ]
机构
[1] Jikei Univ, Sch Med, Minato Ku, Tokyo, Japan
关键词
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The aim of this study is to evaluate the effect of Prostaglandin E-1 on arteriosclerosis obliterans in diabetic patients. In the present study, it is clear that the continuous intravenous administration of PGE(1) at 120 mug/day for 3 weeks has significantly improved subjective symptoms evaluated by the visual analogue scale, such as, coldness, numbness and pain in the lower extremities. Moreover, the circulatory status in the lower extremities was evaluated using the cold stress test by the thermography. Thus, it is indicated that the continuous intravenous administration of PGE(1) should significantly improve the circulatory status as well as subjective symptoms. (arteriosclerosis obliterans, prostaglandin E-1,diabetic patients, cold stress test, visual analogue scale, thermography).
引用
收藏
页码:313 / 316
页数:4
相关论文
共 50 条
  • [21] Effect of oral administration of prostaglandin E1 on erectile dysfunction
    Sato, Y
    Horita, H
    Adachi, H
    Suzuki, N
    Tanda, H
    Kumamoto, Y
    Tsukamoto, T
    BRITISH JOURNAL OF UROLOGY, 1997, 80 (05): : 772 - 775
  • [22] EFFECT OF PURIFIED PROSTAGLANDIN E1 ON HUMAN UTERUS AND TUBES
    SANDBERG, F
    INGELMANSUNDBERG, A
    RYDEN, G
    INTERNATIONAL JOURNAL OF FERTILITY, 1963, 8 (04) : 869 - &
  • [23] EFFECT OF PROSTAGLANDIN E1 ON PLATELET BEHAVIOUR IN VITRO AND IN VIVO
    EMMONS, PR
    HAMPTON, JR
    HARRISON, MJ
    HONOUR, AJ
    MITCHELL, JR
    BRITISH MEDICAL JOURNAL, 1967, 2 (5550): : 468 - &
  • [24] Pharmacokinetics of Alprostadil (Prostaglandin E1) in Patients Undergoing Haemodialysis
    Willi Cawello
    U. Kuhlmann
    H. Schweer
    N. Samadi
    J. Gerloff
    S. Wilberz
    H. W. Seyberth
    H. Lange
    Clinical Drug Investigation, 1999, 18 : 279 - 285
  • [25] Pharmacokinetics of alprostadil (prostaglandin E1) in patients undergoing haemodialysis
    Cawello, W
    Kuhlmann, U
    Schweer, H
    Samadi, N
    Gerloff, J
    Wilberz, S
    Seyberth, HW
    Lange, H
    CLINICAL DRUG INVESTIGATION, 1999, 18 (04) : 279 - 285
  • [26] Iontophoretic application of prostaglandin E1
    Saeki, S
    Yamamura, K
    Osada, T
    Hayashi, T
    Koyasu, K
    Nabeshima, T
    Nishikimi, N
    Sakurai, T
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 1996, : 707 - 708
  • [27] EFFECTS OF PROSTAGLANDIN E1 ON MICROCIRCULATION
    WEINER, R
    KALEY, G
    FEDERATION PROCEEDINGS, 1968, 27 (02) : 282 - &
  • [28] Stability of prostaglandin E1 ethylester
    Chinese Pharmaceutical Journal, 1998, 50 (02): : 97 - 105
  • [29] CARDIOVASCULAR EFFECTS OF PROSTAGLANDIN E1
    NAKANO, J
    MCCURDY, JR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1967, 156 (03): : 538 - &
  • [30] Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin
    Kreutz, Rolf P.
    Nystrom, Perry
    Kreutz, Yvonne
    Miao, Jia
    Kovacs, Richard
    Desta, Zeruesenay
    Flockhart, David A.
    Jin, Yan
    PLATELETS, 2013, 24 (02) : 145 - 150